La terapia dell osteoporosi nel soggetto talassemico Therapy of Thalassemia Major-Induced Osteoporosis
|
|
- Annabel Russell
- 6 years ago
- Views:
Transcription
1
2 La terapia dell osteoporosi nel soggetto talassemico Therapy of Thalassemia Major-Induced Osteoporosis Ashraf Soliman, Vincenzo De Sanctis Mohamed A Yassin,
3 Institutes Departments of Pediatric Endocrinology, Hematology* and Clinical chemistry #Hamad Medical Center (HMC), Doha - Qatar. Pediatric and Adolescent Outpatient Clinic, Quisisana Hospital**, Ferrara - Italy
4 Disclosure statement Conflict statement Nothing to declare No Conflict among authors
5 A World Health Organization (WHO) working group and consensus conference have defined osteoporosis A disease characterized by: 1. low bone mass and 2. micro architectural deterioration of bone tissue, 3. leading to enhanced bone fragility and 4. a consequent increase in fracture risk
6 Thalassemia- Osteoporosis The second most common cause of endocrinopathy in patients with beta thalassemia major (BTM). Osteopenia and severe osteoporosis represent the leading cause of morbidity in BTM patients. The prevalence of osteoporosis in these patients is as high as 50%, with higher rates in males Increased osteoclastic activity with or without decreased bone formation are proposed mechanisms Annals of the New York Academy of Sciences, 2005, 1054, 462 6,
7 The RANK/RANKL pathway RANKL is a key that promotes osteoclast formation and activation, and prolongs osteoclast survival. Osteoprotegerin (OPG) acts as a decoy receptor for RANKL and prevents its interaction with RANK thereby inhibiting osteoclast formation, function and survival. Alteration of the RANK/RANKL/OPG system in favor of increased osteoclastic activity and enhanced osteoblastic dysfunction is proposed as an important mechanism in the etiology of osteoporosis in BTM. Endocr Rev 2008;29: Clin Endocrinol (Oxf). 2003;58(3):273-9
8
9
10 In Thalassemic Patients The ratio of srankl/opg is increased in TM with low BMD. Alterations in the RANK/RANKL/OPG system in favor of osteoclasts are characteristic in thalassaemia due to not clearly delineated mechanisms Hematology. 2006;11(3): British Journal of Haematology. 2001;112(1): Osteoporosis International. 2001;12(7): Journal of Bone and Mineral Research. 2004;19(5):
11 OPG/RANKL system acts as an important paracrine mediator of bone metabolism A central role of the OPG/RANKL system in development of bone abnormalities in TM patients. There is higher circulating levels of RANKL-No differences in plasma levels of OPG ---- high RANKL / OPG ratio and increased osteoclastic activity. Urinary levels of pyridinium cross-links, (bone resorption) were higher in TM patients than controls and positively correlated with plasma levels of RANKL.
12 BTM patients display Unbalanced bone turnover characterized by 1. Enhanced resorption rates (indicated by high levels of pyridinium cross-links) and 2. Decreased neoformation phase (evidenced by low levels of osteocalcin (an osteoblastderived protein) N. Morabito, et al. Journal of Bone and Mineral Research, 2004,19, 722
13 Impairment of Osteoblast Activity Increased serum levels of Dickkopf-1 (Dkk1) and sclerostin have been found in TM patients. Dickkopf-1 is an inhibitor of Wnt signalling, which is crucial for osteoblast differentiation; Sclerostin is produced by the osteocyte and has anti-anabolic effects on bone formation. Higher circulating levels of Dkk1 and sclerostin correlated with reduced BMD of lumbar spine and distal radius. 1. increased bone resorption and 2. reduced bone formation markers. Voskaridou E. Horm Metab Res. 2012, 44(12):
14 Osteoporosis in TM patients is multifactorial + partially understood Genetic Acquired
15 Genes : The collagen type Ia1 (COLIA1) gene, which encodes type I collagen, the major protein of bone Polymorphism at the Sp1 site of COLIA 1 gene has been associated with severe osteoporosis and pathologic fractures of the spine and hip in TM patients. Polymorphism at the Sp1 site of the COLIA 1 gene was present in approximately 30% of TM patients, who were heterozygotes (Ss), and in 4% who were homozygotes (SS) for these changes. N.B. Patients with TM carrying the Sp1 mutation may develop severe osteoporosis of the spine and the hip more frequently than patients who do not carry this mutation. Early detection of this mutation is important to start treatment before fractures occur. Voskaridou E,. Pediatr Endocrinol Rev. 2008;6(Suppl 1):86-93 Guzeloglu-Kayisli O. Pediatr Int 2008;50:
16 Acquired factors a) Bone marrow expansion, secondary to ineffective erythropoiesis b) Direct toxic effects of iron overload on osteoblast number and activity; c) Deleterious effects of desferrioxamine on the bone metabolism, negative impact of chelation therapy on fibroblast proliferation and collagen synthesis. d) Associated endocrine complications, calcium and zinc deficiencies and low vitamin D levels. e) Liver and kidney issues; f) Nutritional deficiencies.
17 1.Marrow Expansion 1. Mechanical interruption of bone, 2. cortical thinning, 3. bone distortion, and 4. increased fragility. The negative relationships between : 1. Hb and RANKL levels 2. Erythropoietin and OPG/RANKL ratio Suggests that medullary expansion may act through enhanced RANKL levels in increasing bone resorption. Carlo Perisano, et al. Physiopathology of Bone Modifications in -Thalassemia Anemia, Volume 2012 (2012), ID ,
18 2. Iron Toxicity: Animal Studies Fe overload on bone remodeling demonstrated: 1. decreased osteoblast recruitment and 2. decreased collagen synthesis, Resulting in decreased bone formation. Human Studies Iron deposition along the mineralization fronts is associated with increased osteoid seams. Focal thickened osteoid seams are found together with focal iron deposits along osteoid surfaces. Fe deposition in bone impairs osteoid maturation and inhibits local mineralization. As a result, focal osteomalacia develops.
19 (iron stain; X500) of undecalcified bone section illustrates the thick linear deposition of iron (blue line) along the mineralization front (thick arrows). The un-mineralized zone is also stained blue, but with lighter intensity (areas between thin arrows). Active osteoblasts (arrowheads) are also present along the osteoid surface.
20 Possible mechanism Iron interferes with osteoid maturation and mineralization by: The incorporation of iron into crystals of calcium hydroxyapatite, Affects the growth of calcium hydroxyapatite crystals and increases osteoid in bone tissue.
21 Can inhibit: 3. Chelation therapy with 1. DNA synthesis, desferrioxamine (DFX) 2. osteoblast and fibroblast proliferation, 3. differentiation of osteoblast precursors and 4. collagen formation. 5. In high doses it enhances osteoblast apoptosis. The toxic effects of DFX can also be due to a deficiency of trace elements such as copper and zinc. Pratelli L, Pediatr Endocrinol Metab Nov;19(11):
22 4. Impaired Calcium Homeostasis: TM patients have high prevalence of VDD: North America, 12.8% < 10 ng/ml, 82% < 30ng/ml India : 80% VDD. Thaliland: 90% VDD VDD may start early in TM, before the occurrence of hypoparathyroidism. VDD is critical for : Ca homeostasis & mineralization of the skeleton, especially during pubertal growth spurt VDD can osteomalacia and Osteoporosis. Soliman A et al. Mediterr J Hematol Infect Dis. 2013
23 5. Endocrine dysfunction 1.Hypogonadism 2.Impaired GH-IGF-I axis and Hypoparathyroidism, Hypothyroidism, Diabetes mellitus Contributes to decreased bone formation and increased bone resorption.
24 In Thalassemia Major Gonadotrophin deficiency as well as Defective growth hormone (GH) insulin-like growth factor-i (IGF-I) axis are common. The anabolic effects of sex steroids, GH and IGF-I on bone formation are important for the acquisition of bone mass, especially during childhood and puberty. Pediatr Endocrinol Rev. 2011; 8 (Suppl 2) :284-9 Clin Endocrinol (Oxf). 2008;69:
25 Androgens RANKL/OPG Androgens block RANKL-induced osteoclastic formation. Testosterone and 5DHT mediate an androgen receptor-induced specific inhibition of OPG mrna expression. RANKL expression was found to be up-regulated in osteoblastic cells from androgen receptor-deficient mice Eur J Endocrinol. 2002;147: Biochemical and Biophysical Research Communications. 2009;389: Endocrinology. 2001;142: J Bone Miner Res. 2005;20:
26 Defective GH-IGF-I axis in thalassemia Low IGF-I : Osteoclasts express IGF-1 receptors and IGF-1 has direct effects on their function. GH and IGF-1 stimulate the production of OPG and its accumulation in the bone matrix. In thalassemic patients, it is suggested that decreased OPG production with increased RANKL/OPG ratio can induce more osteoclastic activity. J Clin Endocrinol Metab Sep;87(9): Exp Cell Res 2004, 294:
27 In Thalassemia: Low Androgens Increases RANKL induced osteoclastic activity Low IGF-I Decreases OPG expression that increases RANKL activity
28 Treatment of Osteoporosis in thalassemia
29 Bone markers Bone formation markers Serum bone specific alkaline phosphatase Serum osteocalcin Serum type 1 procollagen telopeptide (C-terminal/Nterminal): C1NP or P1NP Bone resorption markers Urinary hydroxyproline Urinary total pyridinoline (PYD) Urinary free deoxypyridinoline (DPD) Urinary collagen type 1 crosslinked N-telopeptide (NTX) Urinary or serum collagen type 1 cross-linked C-telopeptide (CTX) Tartrate-resistant acid phosphatase 5b
30 Bisphosphonates (BPs) A group of molecules analogous to inorganic pyrophosphate. They concentrate within bones, binding specifically to its inorganic components. BPs also enter osteoclasts and inhibit their bone destruction ability via several cellular mechanisms Alendronate, Pamidronate, and Zoledronate are effective anti-resorptive BP.
31 Bisphosphonate treatment of TM Mamtani M et al. Osteoporos Int 2010;21: Yigitoglu PH et al. Turk J Phys Med Rehab 2012;58: Otrock ZK, et al. Ann Hematol 2008;87: Patıroğlu T, et al. Turk J Hematol 2008;25:79-82 Gilfillan CP, et al Calcif Tissue Int 2006;79:
32 Zoledronate Zoledronate (4mg IV Q 3mon) for 1 year improves : Significant increase in BMD in : lumbar spine, femoral neck, trochanter, and total hip Decreases the number of painful sites. Decreases : C-telopeptide of collagen type-i(ctx), balp, CICP, and (osteocalcin) OC Esophageal irritation is a side effect. Ann Hematol Sep;85(9): Haematologica Sep;91(9): Mamtani M et al. Osteoporos Int 2010;21: Ann Hematol Jan;86(1):23-30
33 Pamidronate (30 or 60 mg i.v. infusion - once a month over 12 months) Decreases: N-telopeptide of Collagen (INTX), Tartrate-resistant acid phosphatase isoform -5b (TRACP-5b) OPG, and OC Br J Haematol Nov;123(4):730-7 BMD : Increases lumbar spine, (similar in patients of both treatment groups) These data suggest that pamidronate, at a monthly dose 30 mg IV is effective
34 Alendronate PO vs Clodronate IM BOTH NOT Sign EFFECTIVE Alendronate oral 10 mg of alendronate daily BMD lumbar spine and femoral neck increased (NS) Better than placebo Clodronate IM 100 mg of clodronate intramuscularly every 10 days BMD lumbar spine and femoral neck (no change) Better than placebo J. Bone Miner. Metab. 21: Pediatr Endocrinol Rev Oct;6 Suppl 1:144-8.
35 Bisphosphonate in TM Drug Patient No age BMD before BMD after Haematologica 93: Acta Haematol. 119: 40. Zoledronic acid Q 3 months IV 66 Hip- 2y Lumbar 2y Increased Increased Aledronate PO Lumbar: -2.7 Hip: Lumbar:-1yr Hip: Increased 4% Increased 3.1 % JPEM, , 795 Osteoporos. Int, 2005 Br. J. Haematol. 123: PER, 2008 Pamidronate IV 15 mg IV 30 mg IV 60 mg infusion/month Lumbar: -1yr Hip : 1 yr Lumbar : -2.8 Hip: Increased in all Increased with 60mg Morabito et al Osteoporos. Int. 13: P O daily alendronate Vs IM /10d clodronate 9 8 Lumbar And Hip 2 years Increased Same Vs Placebo 8 Decreased
36 Side Effects of Bisphosphonate Fever and flu like symptoms Hypocalcaemia Bone and joint pain constipation or diarrhea usually only last for a few days it is important to drink plenty of fluids (6 to 8 glasses a day) Tiredness and low energy levels Feeling sick is usually mild and gets better after a few days
37 Uncommon short-term safety issues : Nephrotoxicity Anterior uveitis. Atrial fibrillation and flutter Osteonecrosis of the jaw
38 Effects of Calcitonin (CT) in TM Twenty-four patients with an age range of years. 14 received 100 IU nasal CT and 250 mg calcium 3 times a week. 10 were followed up as a control with only routine therapy. After 1 year on CT: bone pain disappeared and radiological signs of osteoporosis had improved significantly (p < 0.01) in the treatment group. CT had no important side effects. Canatan et al. Acta Haematol, 1995;93:20-24
39 Denosumab Is a fully human monoclonal antibody to the receptor activator of nuclear factor kappab ligand RANKL. Inhibits osteoclast formation, Decreases bone resorption, Increases bone mineral density (BMD) The efficacy and safety of Denosumab in BTMinduced osteoporosis has not been tested Anastasilakis ADHorm Metab Res. 2009;41(10):721.
40 Collagen telopeptide
41
42 A systematic review and a meta-analysis. Nine RCTs involving participants. Denosumab universally decreased bone markers and increased lumbar and hip BMD. Denosumab was not associated with a significant reduction in fracture risk [OR (95% CI) 0.74 (0.33 to 1.64), p=0.45]. Denosumab has not yet proved its efficacy on fracture risk reduction while?increased infection risk questions its safety. Anastasilakis ADHorm Metab Res. 2009;41(10):721.
43 Not recommended Pediatric use : May impair bone growth in children with open growth plates and may inhibit eruption of dentition Pregnancy Category: May cause fetal harm when administered pregnant women based on animal studies; in utero resulted in increased fetal loss, stillbirths, and postnatal mortality, including absent lymph nodes, abnormal bone growth and decreased neonatal growth Women with reproductive potential must use highly effective contraception during therapy and for at least 5 months after the last dose
44 Objective: To evaluate the efficacy and safety of Denosumab in patients with BTM-induced osteoporosis on : 1. The biochemical (bone turnover markers) 2. Radiological parameters of bone mineralization
45 Osteoporosis as per WHO criteria Osteopenia : T score of < -1.0 Osteoporosis : T score < -2.5 BMD of lumbar spine and right femoral neck were measured by DEXA scan using a calibrated dual energy X-ray absorption method.
46 Design and Patients: Longitudinal study for a year Patients: 30 (19 M, 11 F) ( yr) on regular Bld Transfusion-dependent BTM patients above 18 years with no history of treatment with bisphosphonates BMD T-scores between -2.5 and -4.0 at the lumbar spine [LS] or total hip [TH]). All patients were on vitamin D replacement Pubertal development (Tanner s stage 5) None has IGT, hypothyroidism, hypoparathyroidism or other systemic illness.
47 Investigations Serum ferritin levels (3488 +/- 1557ng/ml). Every patient underwent DEXA scan as baseline and after 12 months of Denosumab therapy. Biochemical evaluation, at baseline 1, 3, 6,12 months Serum creatinine, Na, K, calcium, phosphorus, Parathormone (PTH), Bone specific alkaline phosphatase (ALP) Type 1 collagen carboxy telopetide (1CCT) (ELISA)
48 Treatment Denosumab 60 mg was administered subcutaneously twice yearly for a year.
49 Before treatment mean ± SD After treatment mean ± SD Type 1 collagen telopeptide 1634 ± ±211* PTH 31± ±34.6 Calcium 2.13± ±0.16 Phosphate ( PO4) 1.51± ±0.24 Bone Akaline phosphatase u/l 97 +/ /- 98 BMD Femur / /- 0.17* BMD SDS Femur (-) 2.14±0.18 (-) 1.44 ± 0.21* BMD SDS lumber (-) 2.77±0.27 (-) 1.45 ± 0.63* IGF-I 175± ±106 IGF-I SDS / /- 1.4 Testosterone (males) 16.1± ±5.1
50 Results: Denosumab therapy for a year Significant increase in BMD - 9.2% at the lumbar spine and - 6.0% at the total hip. Decreased serum ICCT levels by 56% at 1 month and normalized them in all patients at 1 year.
51 Side effects in our patients Pain in the back and/or extremities 4/30 Nausea 3/30. Asymptomatic hypocalcaemia in 2/30 None required stopping therapy
52 Conclusion Denosumab therapy for a year significantly increased : 1. bone mineral density at vertebral and hips of patients with BTM and 2. Associated with a rapid and sustained reduction in bone turnover markers. Further studies are required to confirm longterm effects of this therapy
53 RECOMMENDATIONS 1. Prevention & Monitoring The early identification of osteopenia and osteoporosis is of paramount importance, ( BMD every 2 years starting 12 years) Delayed diagnosis and inadequate treatment may lead to significant osteoporosis, skeletal abnormalities, fractures, spinal deformities, nerve compression and growth failure. 1. Effective iron chelation, 2. Improvement of hemoglobin levels, and Nutrition 3. Adequate hormonal replacement, (Sex steroids, GH, T4) 4. Calcium and vitamin D, zinc administration 5. physical activity (Exercise program) Are the main measures for the prevention of the disease.
54 RECOMMENDATIONS & 2. Treatment For patients with established osteoporosis: Definitive treatment should be considered: 1. Bisphosphonate 2. Calcitonin 3. Denosumab 4.?? Teriparatide (a recombinant peptide fragment of PTH)
55 Pediatric Endocrinology Reviews (PER) Volume 11 No 2 September 2013
56
Effects of Anti RANK ligand Denosumab on Beta Thalassemia induced osteoporosis
Effects of Anti RANK ligand Denosumab on Beta Thalassemia induced osteoporosis Mohamed Yassin 1 Ashraf T. Soliman2, Mohamed O. Abdelrahman3, Vincenzo De Sanctis 4 Departments of, 1 Hematology 2Pediatric
More informationHormone related problems (Endocrinopathies and osteoporosis) Vincenzo de Sanctis Ferrara.
Hormone related problems (Endocrinopathies and osteoporosis) Vincenzo de Sanctis Ferrara vdesanctis@libero.it 6 th EUROPEAN SYMPOSIUM ON RARE ANAEMIAS 1 st Dutch-Belgian meeting for patients and health
More informationAssessment and Treatment of Osteoporosis Professor T.Masud
Assessment and Treatment of Osteoporosis Professor T.Masud Nottingham University Hospitals NHS Trust University of Nottingham University of Derby University of Southern Denmark What is Osteoporosis? Osteoporosis
More informationClinician s Guide to Prevention and Treatment of Osteoporosis
Clinician s Guide to Prevention and Treatment of Osteoporosis Published: 15 August 2014 committee of the National Osteoporosis Foundation (NOF) Tipawan khiemsontia,md outline Basic pathophysiology screening
More informationOsteoporosis. Overview
v2 Osteoporosis Overview Osteoporosis is defined as compromised bone strength that increases risk of fracture (NIH Consensus Conference, 2000). Bone strength is characterized by bone mineral density (BMD)
More informationOverview. Bone Biology Osteoporosis Osteomalacia Paget s Disease Cases. People Centred Positive Compassion Excellence
Overview Osteoporosis and Metabolic Bone Disease Dr Chandini Rao Consultant Rheumatologist Bone Biology Osteoporosis Osteomalacia Paget s Disease Cases Bone Biology Osteoporosis Increased bone remodelling
More informationAnnual Rheumatology & Therapeutics Review for Organizations & Societies
Annual Rheumatology & Therapeutics Review for Organizations & Societies Biochemical Markers of Bone Turnover: Definitions and Recommendations for Monitoring Therapy Learning Objectives for Biochemical
More informationOsteoporosis Update. Greg Summers Consultant Rheumatologist
Osteoporosis Update Greg Summers Consultant Rheumatologist DEFINITION OSTEOPOROSIS is LOW BONE MASS (& micro-architectural deterioration) causing AN INCREASED RISK OF FRACTURE 23 years 82 years 23 y/o
More informationBreast Cancer and Bone Loss. One in seven women will develop breast cancer during a lifetime
Breast Cancer and Bone Loss One in seven women will develop breast cancer during a lifetime Causes of Bone Loss in Breast Cancer Patients Aromatase inhibitors Bil Oophorectomy Hypogonadism Steroids Chemotherapy
More informationThe Role of the Laboratory in Metabolic Bone Disease
The Role of the Laboratory in Metabolic Bone Disease Howard Morris PhD, FAACB, FFSc(RCPA) President, IFCC Professor of Medical Sciences, University of South Australia, Clinical Scientist, SA Pathology
More informationOsteoporosis. When we talk about osteoporosis, we have to be familiar with the constituents of bone and what it is formed of.
Osteoporosis When we talk about osteoporosis, we have to be familiar with the constituents of bone and what it is formed of. Osteoblasts by definition are those cells present in the bone and are involved
More informationWhat is Osteoporosis?
What is Osteoporosis? 2000 NIH Definition A skeletal disorder characterized by compromised bone strength predisposing a person to an increased risk of fracture. Bone strength reflects the integration of
More informationFrom Fragile to Firm. Monika Starosta MD. Advocate Medical Group
From Fragile to Firm Monika Starosta MD Advocate Medical Group Bone Remodeling 10% remodeled each year Calcium homoeostasis Maintain Mechanical strength Replace Osteocytes Release Growth Factors Bone remodeling
More informationDownload slides:
Download slides: https://www.tinyurl.com/m67zcnn https://tinyurl.com/kazchbn OSTEOPOROSIS REVIEW AND UPDATE Boca Raton Regional Hospital Internal Medicine Conference 2017 Benjamin Wang, M.D., FRCPC Division
More informationDiagnosis and Treatment of Osteoporosis. Department of Endocrinology and Metabolism Ajou University School of Medicine.
Diagnosis and Treatment of Osteoporosis Department of Endocrinology and Metabolism Ajou University School of Medicine Yoon-Sok CHUNG WCIM, COEX, Seoul, 27Oct2014 Case 1 71-year old woman Back pain Emergency
More informationOsteoporosis. Current Trend in Osteoporosis Management for Elderly in HK- Medical Perspective. Old Definition of Osteoporosis
Current Trend in Osteoporosis Management for Elderly in HK- Medical Perspective Dr Dicky T.K. Choy Physician Jockey Club Centre for Osteoporosis Care and Control, CUHK Osteoporosis Global public health
More informationSpongeBone Menopants*
SpongeBone Menopants* Adam Fershko, MD, FACP Kettering Health Network *Postmenopausal Osteoporosis Objectives O Epidemiology O Clinical significance O Pathophysiology O Screening and Diagnosis O Treatment
More informationKristen M. Nebel, DO PENN/ LGHP Geriatrics. Temple Family Medicine Review
Kristen M. Nebel, DO PENN/ LGHP Geriatrics 10/3/17 Temple Family Medicine Review OBJECTIVES Define Revised 2017 American College of Physician Recommendations Screening, Prevention and Treatment Application
More informationNovel therapies for Myeloma bone disease. Dr. Naif AlJohani ABIM,FRCPC Adult Hematology/BMT King Faisal specialist hospital & Research center Jeddah
Novel therapies for Myeloma bone disease Dr. Naif AlJohani ABIM,FRCPC Adult Hematology/BMT King Faisal specialist hospital & Research center Jeddah 1 Introduction Multiple myeloma (MM) is a plasma cell
More informationCa, Mg metabolism, bone diseases. Tamás Kőszegi Pécs University, Department of Laboratory Medicine Pécs, Hungary
Ca, Mg metabolism, bone diseases Tamás Kőszegi Pécs University, Department of Laboratory Medicine Pécs, Hungary Calcium homeostasis Ca 1000g in adults 99% in bones (extracellular with Mg, P) Plasma/intracellular
More informationS^t _j4 A-N.1^.^ A _ WE 2
S^t _j4 A-N.1^.^ A _ WE 2 Name of Sponsor: Amgen Inc. Name of Finished Product: Denosumab (AMG 162) Name of Active Ingredient: Fully human monoclonal antibody to RANKL Title of Study: A Randomized Study
More informationBisphosphonates in the Management of. Myeloma Bone Disease
Bisphosphonates in the Management of Myeloma Bone Disease James R. Berenson, MD Medical & Scientific Director Institute for Myeloma & Bone Cancer Research Los Angeles, CA Myeloma Bone Disease Myeloma cells
More informationVol. 19, Bulletin No. 108 August-September 2012 Also in the Bulletin: Denosumab 120mg for Bone Metastases
ה מ ר א פ הביטאון לענייני תרופות ISRAEL DRUG BULLETIN 19 years of unbiased and independent drug information P H A R x M A Vol. 19, Bulletin No. 108 August-September 2012 Also in the Bulletin: Denosumab
More informationOsteoporosis: current treatment and future prospects. Juliet Compston Professor Emeritus of Bone Medicine Cambridge Biomedical Campus
Osteoporosis: current treatment and future prospects Juliet Compston Professor Emeritus of Bone Medicine Cambridge Biomedical Campus Disclosures Consultancy and speaking fees for Gilead, related to development
More informationBone Metastases. Sukanda Denjanta, M.Sc., BCOP Pharmacy Department, Chiangrai Prachanukroh Hospital
Bone Metastases Sukanda Denjanta, M.Sc., BCOP Pharmacy Department, Chiangrai Prachanukroh Hospital 1 Outline Pathophysiology Signs & Symptoms Diagnosis Treatment Spinal Cord Compression 2 General Information
More informationCASE 1 WHY IS IT IMPORTANT TO TREAT? FACTS CONCERNS
4:30-5:15pm Ask the Expert: Osteoporosis SPEAKERS Silvina Levis, MD OSTEOPOROSIS - FACTS 1:3 older women and 1:5 older men will have a fragility fracture after age 50 After 3 years of treatment, depending
More information8/6/2018. Glucocorticoid induced osteoporosis: overlooked and undertreated? Disclosure. Objectives. Overview
Disclosure Glucocorticoid induced osteoporosis: overlooked and undertreated? I have no financial disclosure relevant to this presentation Tasma Harindhanavudhi, MD Division of Diabetes and Endocrinology
More informationBONE REMODELLING. Tim Arnett. University College London. Department of Anatomy and Developmental Biology
BONE REMODELLING Tim Arnett Department of Anatomy and Developmental Biology University College London The skeleton, out of sight and often out of mind, is a formidable mass of tissue occupying about 9%
More informationThe Bare Bones of Osteoporosis. Wendy Rosenthal, PharmD
The Bare Bones of Osteoporosis Wendy Rosenthal, PharmD Definition A systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue, with a consequent increase
More informationOsteoporosis. Treatment of a Silently Developing Disease
Osteoporosis Treatment of a Silently Developing Disease Marc K. Drezner, MD Senior Associate Dean Emeritus Professor of Medicine Emeritus University of Wisconsin-Madison Auditorium The Forest at Duke October
More informationUpdates in Osteoporosis. I have no conflicts of interest. What Would You Do? Mrs. C. What s New in Osteoporosis. Page 1
Updates in Osteoporosis Jeffrey A. Tice, MD Associate Professor of Medicine Division of General Internal Medicine, University of California, San Francisco I have no conflicts of interest What s New in
More informationCurrent and Emerging Strategies for Osteoporosis
Current and Emerging Strategies for Osteoporosis I have nothing to disclose. Anne Schafer, MD Assistant Professor of Medicine Division of Endocrinology & Metabolism December 12, 2014 Outline Osteoporosis
More informationForteo (teriparatide) Prior Authorization Program Summary
Forteo (teriparatide) Prior Authorization Program Summary FDA APPROVED INDICATIONS DOSAGE 1 FDA Indication 1 : Forteo (teriparatide) is indicated for: the treatment of postmenopausal women with osteoporosis
More informationAn Update on Osteoporosis Treatments
An Update on Osteoporosis Treatments Dr Mike Stone University Hospital Llandough Treatments for osteoporosis Calcium and vitamin D HRT Raloxifene Etidronate Alendronate Risedronate Ibandronate (oral and
More informationUpdates in Osteoporosis
Updates in Osteoporosis Jeffrey A. Tice, MD Associate Professor of Medicine Division of General Internal Medicine, University of California, San Francisco I have no conflicts of interest What s New in
More informationPresenter: 翁家嫻 Venue date:
FOR THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AT INCREASED RISK OF FRACTURES 1 Presenter: 翁家嫻 Venue date: 2018.03.13 PMO: postmenopausal osteoporosis. 1. Prolia (denosumab), Summary of Product
More informationPage 1. Updates in Osteoporosis. I have no conflicts of interest. What is osteoporosis? What s New in Osteoporosis
Updates in Osteoporosis Jeffrey A. Tice, MD Professor of Medicine Division of General Internal Medicine, University of California, San Francisco I have no conflicts of interest What s New in Osteoporosis
More informationBIOLOGY and BIOMECHANICS OF NORMAL & OSTEOPOROTIC BONE
BIOLOGY and BIOMECHANICS OF NORMAL & OSTEOPOROTIC BONE Andreas Panagopoulos, MD, PhD Assistant Professor in Orthopaedics University Hospital of Patras, Orthopaedic Clinic Objectives Bone structure and
More informationDrugs Affecting Bone. Rosa McCarty PhD. Department of Pharmacology & Therapeutics
Drugs Affecting Bone Rosa McCarty PhD Department of Pharmacology & Therapeutics rmccarty@unimelb.edu.au Objectives At the end of this lecture you should have gained: An understanding of bone metabolism
More informationElecsys bone marker panel. Optimal patient management starts in the laboratory
bone marker panel Optimal patient management starts in the laboratory Complete solution for osteoporosis The most complete bone metabolism panel on a single platform bone marker assays are important diagnostic
More informationPathophysiology of Postmenopausal & Glucocorticoid Induced Osteoporosis. March 15, 2016 Bone ECHO Kate T Queen, MD
Pathophysiology of Postmenopausal & Glucocorticoid Induced Osteoporosis March 15, 2016 Bone ECHO Kate T Queen, MD Review: normal bone formation Bone Modeling Remodeling Peak Bone Mass Maximum bone mass
More informationFragile Bones and how to recognise them. Rod Hughes Consultant physician and rheumatologist St Peter s hospital Chertsey
Fragile Bones and how to recognise them Rod Hughes Consultant physician and rheumatologist St Peter s hospital Chertsey Osteoporosis Osteoporosis is a skeletal disorder characterised by compromised bone
More informationOSTEOPOROSIS, OSTEOARTHRITIS AND MUSKOSKELETAL DISEASE: A CALL FOR ACTION
V O L U M E 5 6 N U M B E R 2 J U N E 2 0 1 4 OSTEOPOROSIS, OSTEOARTHRITIS AND MUSKOSKELETAL DISEASE: A CALL FOR ACTION PANMINERVA MED 2014;56:97-114 J. Y., A. NEUPREZ, CH. BEAUDART, F. BUCKINX, J. SLOMIAN,
More informationMetabolic Bone Disease Related to Chronic Kidney Disease
Metabolic Bone Disease Related to Chronic Kidney Disease Deborah Sellmeyer, MD Director, Johns Hopkins Metabolic Bone Center Dept of Medicine, Division of Endocrinology Disclosure DSMB member for denosumab
More informationBone Disorders in CKD
Osteoporosis in Dialysis Patients Challenges in Management David M. Klachko MD FACP Professor Emeritus of Medicine University of Missouri-Columbia Bone Disorders in CKD PTH-mediated high-turnover (osteitis
More informationOriginal Article INTRODUCTION:
Original Article International Journal of Dental and Health Sciences Volume 03,Issue 03 EFFECT OF HEMOGLOBIN AND FERRITIN OF SERUM CONCENTRATIONS ON THE DENSITY OF JAWBONE THAT INTENDED FOR DENTAL IMPLANT
More informationPractical Management Of Osteoporosis
Practical Management Of Osteoporosis CONFERENCE 2012 Education Centre, Bournemouth.19 November The following companies have given funding towards the cost of this meeting but have no input into the agenda
More informationProduct: Denosumab (AMG 162) Clinical Study Report: month Primary Analysis Date: 21 November 2016 Page 1
Date: 21 November 2016 Page 1 2. SYNOPSIS Name of Sponsor: Amgen Inc., Thousand Oaks, CA, USA Name of Finished Product: Prolia Name of Active Ingredient: denosumab Title of Study: Randomized, Double-blind,
More informationIndex. B BMC. See Bone mineral content BMD. See Bone mineral density Bone anabolic impact, Bone mass acquisition
A Acid base balance dietary protein detrimental effects of, 19 Acid base balance bicarbonate effects, 176 in bone human studies, 174 mechanisms, 173 174 in muscle aging, 174 175 alkali supplementation
More informationOSTEOPOROSIS AND WHAT TO DO AFTER A VERTEBRAL FRACTURE. Lydia Au Geriatrics Ng Teng Fong Hospital
OSTEOPOROSIS AND WHAT TO DO AFTER A VERTEBRAL FRACTURE Lydia Au Geriatrics Ng Teng Fong Hospital LET S START WITH WHAT YOU WANT TO KNOW AND DO WITH A VERT FRACTURE Vertebral fractures Most common (550K
More informationBone Health in Patients with Multiple Myeloma
Bone Health in Patients with Multiple Myeloma Amrita Y. Krishnan, MD Director Judy and Bernard Briskin Myeloma Center City of Hope Comprehensive Cancer Center Bone Health Bisphosphonates in Space Bone
More informationTHE EFFECT OF HIGH CALORIC DIET ON NUTRITIONAL PARAMETERS OF CHILDREN WITH THALASSAEMIA MAJOR.
THE EFFECT OF HIGH CALORIC DIET ON NUTRITIONAL PARAMETERS OF CHILDREN WITH THALASSAEMIA MAJOR. Ashraf T Soliman MD, PhD Professor of Pediatrics and Endocrinology Thalassemia Ht 102 cm HtSDS = -5.98 Transfusion
More informationBone strength is proportional to bone mass, measured with DXA. Bone turnover markers indicate the status of bone quality.
Bone strength is proportional to bone mass, measured with DXA Bone quality depend on bone architecture, rate of bone turnover, quality of bone matrix. Bone turnover markers indicate the status of bone
More informationOsteoporosis update. Dr. Claire Vandevelde Consultant Rheumatologist, LTHT
Osteoporosis update Dr. Claire Vandevelde Consultant Rheumatologist, LTHT Outline Background BMD Tools for assessing fracture risk Case study Denosumab Treatment breaks BMD BMD predicts fracture risk but
More informationBad to the Bones: Diabetes and Thiazolidinediones 9/9/2010. Steven Ing, MD, MSCE Assistant Professor Division of Endocrinology, Diabetes & Metabolism
Bad to the Bones: Diabetes and Thiazolidinediones 9/9/2010 Steven Ing, MD, MSCE Assistant Professor Division of Endocrinology, Diabetes & Metabolism Any reduction of bone mass in diabetics that is revealed
More informationBone Disease in Thalassemia: A Molecular and Clinical Overview
REVIEW Bone Disease in Thalassemia: A Molecular and Clinical Overview Phillip Wong, Peter J. Fuller, Matthew T. Gillespie, and Frances Milat Department of Endocrinology (P.W., P.J.F., F.M.), Monash Health,
More informationMonitoring Osteoporosis Therapy
Monitoring Osteoporosis Therapy SUZANNE MORIN DEPT OF MEDICINE, DIVISION OF GENERAL INTERNAL MEDICINE, MUHC CENTRE FOR OUTCOMES RESEARCH AND EVALUATION, RI MUHC November 2017 Conflict of Interest Disclosures
More informationCorrelation between Thyroid Function and Bone Mineral Density in Elderly People
IBBJ Spring 2016, Vol 2, No 2 Original Article Correlation between Thyroid Function and Bone Mineral Density in Elderly People Ali Mirzapour 1, Fatemeh Shahnavazi 2, Ahmad Karkhah 3, Seyed Reza Hosseini
More informationUpdate on Osteoporosis 2016
WELCOME! Update on Osteoporosis 2016 Jennifer J. Kelly, D.O., F.A.C.E. Associate Professor of Medicine Division of Endocrinology, Diabetes and Metabolism Upstate Medical University Director of the Clinical
More informationHRT and Risedronate Combined Anabolic and Antiresorptive Therapy
Optimizing Combined and Sequential Osteoanabolic and Antiresorptive Therapy Benjamin Leder, M.D. Endocrine Unit Massachusetts General Hospital Boston, MA Antiresorptive and Osteoanabolic Therapies Increase
More informationAdditional Research is Needed to Determine the Effects of Soy Protein on Calcium Binding and Absorption NDFS 435 3/26/2015. Dr.
Additional Research is Needed to Determine the Effects of Soy Protein on Calcium Binding and Absorption NDFS 435 3/26/2015 Dr. Tessem Osteoporosis is a public health problem in all stages of life. Many
More informationLong-term Osteoporosis Therapy What To Do After 5 Years?
Long-term Osteoporosis Therapy What To Do After 5 Years? Developing a Long-term Management Plan North American Menopause Society Philadelphia, PA October 11, 2017 Michael R. McClung, MD, FACP Institute
More informationChau Nguyen, D.O. Rheumatologist Clinical Assistant Professor of Internal Medicine at Western University of Health Sciences
Chau Nguyen, D.O Rheumatologist Clinical Assistant Professor of Internal Medicine at Western University of Health Sciences I do not have any relationship with the manufacturer of any commercial products
More informationGenetic examination of diseases affecting bone development. and structure in newborns
Genetic examination of diseases affecting bone development and structure in newborns Examination of molecular genetic markers in osteopenic preterm infants PhD Thesis Simone Funke, MD University of Pécs
More information7/5/2016. We need drugs that. Disclosures. New Osteoporosis Treatments. What we have today. Maintain or promote bone formation
New Osteoporosis Treatments Disclosures Mary L. Bouxsein, PhD Department of Orthopedic Surgery Harvard Medical School, Boston, MA Advisory Board: Research funding: Merck, Eli Lilly, Radius Merck, Amgen
More informationTreatments for Osteoporosis Expected Benefits, Potential Harms and Drug Holidays. Suzanne Morin MD FRCP FACP McGill University May 2014
Treatments for Osteoporosis Expected Benefits, Potential Harms and Drug Holidays Suzanne Morin MD FRCP FACP McGill University May 2014 Learning Objectives Overview of osteoporosis management Outline efficacy
More informationDrug Intervals (Holidays) with Oral Bisphosphonates
Drug Intervals (Holidays) with Oral Bisphosphonates Rizwan Rajak Consultant Rheumatologist & Lead for Osteoporosis GP Postgraduate Meeting April 2018 Contents Case presentation Pathway for Bisphosphonate
More informationDisclosures CONSULTANT WRIGHT MEDICAL CONSULTANT ORTHO FIX
Disclosures CONSULTANT WRIGHT MEDICAL CONSULTANT ORTHO FIX Overview Radiographic Pattern Histopathology Pathways: RANKL/OPG AGE/RAGE Treatment based on Evidence Radiographic Pattern Pattern of Diabetic
More informationWHAT KEEPS OUR BONES STRONG?
WHAT KEEPS OUR BONES STRONG? The role of diet and lifestyle in osteoporosis prevention Thomas Walczyk PhD, Associate Professor Food Science and Technology Programme Department of Chemistry, Faculty of
More information2017 Santa Fe Bone Symposium McClung
217 Santa Fe Bone Symposium Insights into the Use of Anti-remodeling and Anabolic Agents for Osteoporosis Developing a Long-term Management Plan Michael R., MD, FACP Oregon Osteoporosis Center Portland,
More informationBone metastases in hematology
Botziekte bij hematologische tumoren Prof. Dr. Michel Delforge Hematologie, UZ Leuven Bone metastases in hematology The bone marrow is the source of many hematological malignancies However, bone damage
More informationSponsor / Company: sanofi-aventis and Proctor & Gamble Drug substance(s): Risedronate (HMR4003)
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: sanofi-aventis and
More informationA KL/R / AN A K/O / P O G G
Outline and New Treatments on the Horizon Steven R. Cummings, MD CPMC and UCSF San Francisco Coordinating Center Support from Lilly and Amgen New treatments, new mechanisms of action Cathepsin K inhibition
More informationOsteoporosis Agents Drug Class Prior Authorization Protocol
Osteoporosis Agents Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review of
More informationAnabolic Therapy With Teriparatide Indications Beyond Osteoporosis
Anabolic Therapy With Teriparatide Indications Beyond Osteoporosis Andreas Panagopoulos MD, PhD Upper Limb & Sports Medicine Orthopaedic Surgeon Assistant Professor, University of Patras Outline Teriparatide
More informationAgents that Affect Bone & Mineral Homeostasis
Agents that Affect Bone & Mineral Homeostasis 1 Agents that Affect Bone & Mineral Homeostasis Calcium and phosphate are the major mineral constituents of bone. They are also two of the most important minerals
More informationNew Developments in Osteoporosis: Screening, Prevention and Treatment
Osteoporosis: Overview New Developments in Osteoporosis: Screening, Prevention and Treatment Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF Definitions Risk factors
More informationTEAM SCIENCE AT A PROGRAMMATIC LEVEL. Sundeep Khosla, M.D. Mayo Clinic College of Medicine
TEAM SCIENCE AT A PROGRAMMATIC LEVEL Sundeep Khosla, M.D. Mayo Clinic College of Medicine APPROACH TO TRANSLATIONAL RESEARCH IN OSTEOPOROSIS Epidemiological Studies Clinical Investigation Mouse and Cellular
More informationENDOCRINE DISORDERS IN THALASSEMIA MAJOR: QUALITY OF LIFE BEYOND SURVIVAL
ENDOCRINE DISORDERS IN THALASSEMIA MAJOR: QUALITY OF LIFE BEYOND SURVIVAL 1,2 Carmen Barbu, 1,2 Alice Albu, 3 Larisa Nitu, 3 Daniela Voicu, 1,3 Florentina Vladareanu, 2 Suzana Florea and 1,2 Simona Fica
More informationPage 1. Current and Emerging Strategies What s New in Osteoporosis. Osteoporosis. What is Osteoporosis? Traditional Risk Factors for Fracture
Current and Emerging Strategies for Osteoporosis What s New in Osteoporosis Risk stratification Douglas C. Bauer, MD University of California, San Francisco Under recognition and poor compliance New potential
More informationBisphosphonates and RANK-L inhibitors in Myeloma
Bisphosphonates and RANK-L inhibitors in Myeloma S. Vincent Rajkumar Professor of Medicine Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of Medicine Mayo
More informationOsteoporosis in Men Professor Peter R Ebeling
Osteoporosis in Men MD FRACP Head, Department of Medicine, School for Clinical Sciences Monash Health Translation Precinct Monash University, Clayton, Victoria 1 MonashHealth Potential Conflicts Departmental
More informationManagement of postmenopausal osteoporosis
Management of postmenopausal osteoporosis Yeap SS, Hew FL, Chan SP, on behalf of the Malaysian Osteoporosis Society Committee Working Group for the Clinical Guidance on the Management of Osteoporosis,
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Prolia 60 mg solution for injection in a pre-filled syringe 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each pre-filled syringe
More informationPHARMACOLOGIC PROPERTIES
Denosumab Prolia TM 60mg/mL Solution for Injection PRODUCT DESCRIPTION Each pre-filled syringe contains 60 mg of denosumab in 1.0 ml solution (60 mg/ml). Clear, colourless to slightly yellow solution,
More informationCurrent Management of Metastatic Bone Disease
Current Management of Metastatic Bone Disease Evaluation and Medical Management Dr. Sara Rask Head, Medical Oncology Simcoe Muskoka Regional Cancer Centre www.rvh.on.ca Objectives 1. Outline an initial
More informationReview Article Physiopathology of Bone Modifications in β-thalassemia
Hindawi Publishing Corporation Anemia Volume 2012, Article ID 320737, 5 pages doi:10.1155/2012/320737 Review Article Physiopathology of Bone Modifications in β-thalassemia Carlo Perisano, 1 Emanuele Marzetti,
More informationOsteoporosis - Pathophysiology and diagnosis. Bente L Langdahl Department of Endocrinology Aarhus University Hospital Aarhus, Denmark
Osteoporosis - Pathophysiology and diagnosis Bente L Langdahl Department of Endocrinology Aarhus University Hospital Aarhus, Denmark Objective General knowledge about osteoporosis Optimise your protocols
More informationPrevalence of Osteoporosis among Thalassemia Patients from Zafar Adult Thalassemia Clinic, Iran
ORIGINAL ARTICLE IJBC 2014;6(3): 143-148 Prevalence of Osteoporosis among Thalassemia Patients from Zafar Adult Thalassemia Clinic, Iran Hashemieh M 1, Azarkeivan A 2 *, Radfar M 3, Saneifard H 4, Hosseini-Zijoud
More informationUpcoming Agents for Osteoporosis
Upcoming Agents for Osteoporosis May 5, 2017 Michael R. McClung, MD, FACP Director, Oregon Osteoporosis Center Portland, Oregon, USA Professorial Fellow, Institute of Health and Ageing Australian Catholic
More information1
www.osteoporosis.ca 1 2 Overview of the Presentation Osteoporosis: An Overview Bone Basics Diagnosis of Osteoporosis Drug Therapies Risk Reduction Living with Osteoporosis 3 What is Osteoporosis? Osteoporosis:
More informationDiagnosis and Treatment of Osteoporosis: What s New and Controversial in ? What s New in Osteoporosis
Diagnosis and Treatment of Osteoporosis: What s New and Controversial in 2018-19? What s New in Osteoporosis The crisis in treatment and compliance Douglas C. Bauer, MD Professor of Medicine and Epidemiology
More informationdenosumab (Prolia ) Policy # Original Effective Date: 07/21/2011 Current Effective Date: 04/19/2017
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationBased on review of available data, the Company may consider the use of denosumab (Prolia) for the
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationNew treatment targets in osteoporosis
National University of Athens Greece New treatment targets in osteoporosis Gourzi Vassiliki PhD Candidate Dept. of Pathophysiology School of Medicine Bone remodeling Physiological process < bone tissue
More informationChapter 39: Exercise prescription in those with osteoporosis
Chapter 39: Exercise prescription in those with osteoporosis American College of Sports Medicine. (2010). ACSM's resource manual for guidelines for exercise testing and prescription (6th ed.). New York:
More informationMultiple Myeloma Bone Disease
The 4th World Congress on CONTROVERSIES IN MULTIPLE MYELOMA May 3-5, 2018 Paris, France Multiple Myeloma Bone Disease Evangelos Terpos MD, PhD Plasma Cell Dyscrasias Unit,, National & Kapodistrian, School
More informationFibrous Dysplasia in Children. Professor Nick Shaw Birmingham Children s Hospital, UK
Fibrous Dysplasia in Children Professor Nick Shaw Birmingham Children s Hospital, UK Overview What is Fibrous Dysplasia? Clinical Presentations Endocrine Problems Skeletal Problems Treatment Options Fibrous
More informationDISEASES WITH ABNORMAL MATRIX
DISEASES WITH ABNORMAL MATRIX MSK-1 FOR 2 ND YEAR MEDICAL STUDENTS Dr. Nisreen Abu Shahin CONGENITAL DISEASES WITH ABNORMAL MATRIX OSTEOGENESIS IMPERFECTA (OI): also known as "brittle bone disease" a group
More informationClinical Study Effect of Zoledronic Acid on Bone Mineral Density in Men with Prostate Cancer Receiving Gonadotropin-Releasing Hormone Analog
Hindawi Publishing Corporation Prostate Cancer Volume 2, Article ID 7664, 7 pages doi:.55/2/7664 Clinical Study Effect of Zoledronic Acid on Bone Mineral Density in Men with Prostate Cancer Receiving Gonadotropin-Releasing
More information